Multimodality therapy for lung cancer;Multimodale Therapie des Lungenkarzinoms

Internist

Volumn 51, Issue 11, 2010, Pages 1348-1357

  Stoelben, E ^a   Huber, R M ^b   Muller R P ^c   Wolf, J ^c  

^a KLINIKEN DER STADT KÖLN GGMBH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Chemotherapy; Lung cancer; Neoplasm staging; Personalized therapy; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL EVALUATION; COHORT ANALYSIS; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SURGERY; LUNG TUMOR; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDIASTINUM TUMOR; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PROPHYLAXIS; SKULL IRRADIATION; SURVIVAL RATE;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 78650419843     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-010-2674-6     Document Type: Article

References (10)

1. Albain KS, Swann RS, Rusch VW et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374:379-386
2. Brunelli A, Charloux A, Bolliger CT et al; European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy (2009) ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 34:17-41
3. Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin, Deutsche Krebsgesellschaft (2010) Prävention, Diagnostik, Therapie und Nachsorge des Lungekarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 64 (Suppl 2): e1-e164
4. Hellwig D, Baum RP, Kirsch C-M (2009) FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer. Nuklearmedizin 48:59-69
5. Meerbeeck JP van, Kramer G W P M, Van Schil P E Y et al (2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99:442-450
6. Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967
7. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
8. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
9. Sobin LH, Gospodarowicz MK, Wittekind CH (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell
10. Stoelben E, Ludwig C (2009) Chest wall resection for lung cancer: indications and techniques. Eur J Cardiothorac Surg 35:450-456